Has further downside to $11-$14 - Gap fill from October 19' Short

Description

⋅ Feb 10, 2020 9:43 PM

The recent plummet was due to less than stellar Phase 3 results. With a March 25 PDUFA target on the horizon, longs may have given up and cut their losses. Technical indicate a big gap to fill in the $11-$14 area from October last year. Short.

Comments

fsanyot1

⋅ Feb 24, 2020 5:15 PM

This is dumb. Their PDUFA is for a different disease (Dravet Syndrome) while the data is about Lennox-Gestaut syndrome. Long.

SimplyCash

⋅ Feb 27, 2020 1:49 AM

@fsanyot1, Still long?